Srdan Verstovsek, MD, PhD and Laura Michaelis, MD
In this episode, “New Developments in Essential Thrombocythemia and Polycythemia Vera”, Srdan Verstovsek, MD, PhD and Laura Michaelis, MD discuss where we are today in the management of ET and PV.
Revised ET risk stratification (which incorporates JAK2 mutation status) represents a significant change in management. Cytoreductive options include hydroxyurea, interferon or anagrelide. In PV, cytoreductive therapy may consist of hydroxyurea or pegylated interferon, with ruxolitinib used second-line after hydroxyurea. Despite progress in these classical myeloproliferative neoplasms, there are still many patients with symptoms that are not adequately addressed with current treatments.